Financings in Brief: Endogen
This article was originally published in The Gray Sheet
Executive Summary
Endogen: Retires approximately $1.8 mil. in debt related to its March 1996 acquisition of T Cell Diagnostics. The Woburn, Massachusetts maker of biomedical research products exchanged the convertible subordinated note for 389,347 shares of Endogen common stock. Approximately 3.4 mil. shares are now outstanding...